. 2019 Mar 1;9(3):e024691. doi: 10.1136/bmjopen-2018-024691

Table 1.

Study characteristics

Study	Design	Location, funding	Prior treatments	Intervention	N	Type	Median age years	Male %	ECOG 0/1%	Treatment duration (follow-up) months
AXIS²⁰	PIII OL RCT	175 sites in 22 countries, Pfizer	One prior systemic treatment (sunitinib, cytokine or other), prior sunitinib subgroup 54%	Axitinib	361	CC	61	73	99	8.2 (NR)
AXIS²⁰	PIII OL RCT	175 sites in 22 countries, Pfizer		Sorafenib	362	CC	61	71	100	5.2 (NR)
CheckMate 025¹⁴	PIII OL RCT	146 sites in 24 countries, BMS	One or two prior targeted treatments (TKI or other, no mTORi)	Nivolumab	410	CC	62	77	NR	5.5 (NR)
CheckMate 025¹⁴	PIII OL RCT	146 sites in 24 countries, BMS		Everolimus	411	CC	62	74	NR	3.7 (NR)
HOPE 205¹⁵	PII OL RCT	37 sites in Czech Republic, Poland, Spain, UK, US, Eisai	one prior TKI, no prior mTORi	Lenvatinib+eve	51	CC	61	69	100	7.6 (NR)
HOPE 205¹⁵	PII OL RCT	37 sites in Czech Republic, Poland, Spain, UK, US, Eisai	one prior TKI, no prior mTORi	Everolimus	50	CC	59	76	100	4.1 (NR)
METEOR¹³	PIII OL RCT	173 sites in 26 countries, Exelixis	one or more prior TKIs; no prior mTORi	Cabozantinib	330	CC	63*	77	100	8.3 (18.7)
METEOR¹³	PIII OL RCT	173 sites in 26 countries, Exelixis	one or more prior TKIs; no prior mTORi	Everolimus	328	CC	62*	73	100	4.4 (18.8)
RECORD-1²⁸	PIII DB RCT, Novartis	86 sites in Australia, Canada Europe, Japan, US, Novartis	one or two prior TKIs; no prior mTORi	Everolimus	277	CC	61*	78	NR	4.6 (NR)
RECORD-1²⁸	PIII DB RCT, Novartis	86 sites in Australia, Canada Europe, Japan, US, Novartis	one or two prior TKIs; no prior mTORi	BSC/placebo	139	CC	60*	76	NR	1.9 (NR)
Guida 2017³²	Chart review	One site in France, NR	One prior targeted treatment (TKI or other)	Everolimus	81	92% CC	57	69	85	NR (33)
Guida 2017³²	Chart review	One site in France, NR	One prior targeted treatment (TKI or other)	Axitinib	45	92% CC	54	78	82	NR (26)
Heng 2016¹⁹	Chart review	UK, Germany, France, Netherlands, Novartis	One prior TKI (sunitinib or pazopanib)	Everolimus	115	NR	60.2	66.7	91.8%≤2	NR (NR)
				Axitinib	96					NR (NR)
				Sorafenib	98					NR (NR)
Iacovelli 2015²⁷	Chart review	23 sites in Italy, NR	Two prior targeted treatments (TKI or other)	Sorafenib	90	CC	63	74	81	NR (NR)
Iacovelli 2015²⁷	Chart review	23 sites in Italy, NR	Two prior targeted treatments (TKI or other)	Everolimus	143	CC	63	74	81	NR (NR)
Lakomy 2017³³	Chart review	Czech national registry, †	one prior targeted treatment (TKI or other)	Everolimus	520	94% CC	65	75	95	6.1 (NR)
Lakomy 2017³³	Chart review	Czech national registry, †	one prior targeted treatment (TKI or other)	Sorafenib	240	94% CC	62	75	90	7.1 (NR)
SPAZO-2³¹	Chart review	50 sites in Spain, Novartis	one prior TKI (pazopanib)	Everolimus	101	88% CC	66	64	NR	NR (28)
SPAZO-2³¹	Chart review	50 sites in Spain, Novartis	one prior TKI (pazopanib)	Axitinib	88	88% CC	63	68	NR	NR (28)
Vogelzang 2016²⁹	Chart review	US, Novartis	One prior TKI; no prior cytokines	Everolimus	325	85% CC	61*	70	80	NR (15*)
Vogelzang 2016²⁹	Chart review	US, Novartis	One prior TKI; no prior cytokines	Axitinib	127	85% CC	60*	65	84	NR (13*)
Wong 2014³⁰	Chart review	US, Novartis	One prior TKI; no prior mTORi, cytokines, bevacizumab	Everolimus	233	91% CC	64	70	NR	NR (12.9)
Wong 2014³⁰	Chart review	US, Novartis	One prior TKI; no prior mTORi, cytokines, bevacizumab	Sorafenib	123	91% CC	66	72	NR	NR (12.1)

*Mean values where median was not reported.

†Ministry of Health of the Czech Republic, Central European Institute of Technology, The Ministry of Education, Youth and Sports. RENIS registry part funded by Pfizer, Bayer and Novartis.

amRCC, advanced or metastatic RCC; BSC, best supportive care; cc, clear cell variant; mRCC, metastatic renal cell carcinoma; mTORi, mammalian target of rapamaycin inhibitor; ncc, non-clear cell variant; NR, not reported; RCT, randomised controlled trials; TKI, tyrosine kinase inhibitor.

Notes: ECOG percentages that do not total 100 are due to missing data.